Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic
Background: Adalimumab therapy has an established record of high efficacy in psoriasis treatment. However, only a limited number of studies have investigated long-term results in clinical practice. Objectives: To evaluate the effectiveness and safety of adalimumab in a center for biological therapy...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2018-08-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2018.1425358 |
| _version_ | 1797683747383934976 |
|---|---|
| author | Elizabeth Adenubiova Petr Arenberger Petra Gkalpakioti Monika Arenbergerova Jitka Jircikova Tomas Dolezal Spyridon Gkalpakiotis |
| author_facet | Elizabeth Adenubiova Petr Arenberger Petra Gkalpakioti Monika Arenbergerova Jitka Jircikova Tomas Dolezal Spyridon Gkalpakiotis |
| author_sort | Elizabeth Adenubiova |
| collection | DOAJ |
| description | Background: Adalimumab therapy has an established record of high efficacy in psoriasis treatment. However, only a limited number of studies have investigated long-term results in clinical practice. Objectives: To evaluate the effectiveness and safety of adalimumab in a center for biological therapy in the Czech Republic. Methods: Retrospectively, we analyzed 90 patients with moderate to severe psoriasis who were treated with adalimumab between 2008 and 2016. The proportion of patients achieving PASI75, 90, and 100 after 3, 6, 12, 18, 24, 30, and 36 months was determined. Results: The mean period of treatment was 4.4 years (maximum duration reached was 8.6 years). PASI75 was observed in 85.6% of patients after 3 months, PASI90 in 50%, and PASI100 in 23.3%. Throughout the 3-year analysis, PASI90 was persistent in 91.4% and PASI100 in 51.7%. The majority of patients who reached PASI100 showed a trend to maintain the response in the long-term follow-up. No safety issues were identified. Conclusions: Adalimumab is effective and safe in the long-term treatment of psoriatic patients in daily clinical practice. Once patients achieved PASI100, they tended to remain stable in treatment. |
| first_indexed | 2024-03-12T00:19:17Z |
| format | Article |
| id | doaj.art-82ad18baf2844199815703b946640ee9 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:19:17Z |
| publishDate | 2018-08-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-82ad18baf2844199815703b946640ee92023-09-15T14:08:31ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532018-08-0129657958210.1080/09546634.2018.14253581425358Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech RepublicElizabeth Adenubiova0Petr Arenberger1Petra Gkalpakioti2Monika Arenbergerova3Jitka Jircikova4Tomas Dolezal5Spyridon Gkalpakiotis6Charles University and Faculty Hospital of Kralovske VinohradyCharles University and Faculty Hospital of Kralovske VinohradyCharles University and Faculty Hospital of Kralovske VinohradyCharles University and Faculty Hospital of Kralovske VinohradyValue outcomes s.r.oValue outcomes s.r.oCharles University and Faculty Hospital of Kralovske VinohradyBackground: Adalimumab therapy has an established record of high efficacy in psoriasis treatment. However, only a limited number of studies have investigated long-term results in clinical practice. Objectives: To evaluate the effectiveness and safety of adalimumab in a center for biological therapy in the Czech Republic. Methods: Retrospectively, we analyzed 90 patients with moderate to severe psoriasis who were treated with adalimumab between 2008 and 2016. The proportion of patients achieving PASI75, 90, and 100 after 3, 6, 12, 18, 24, 30, and 36 months was determined. Results: The mean period of treatment was 4.4 years (maximum duration reached was 8.6 years). PASI75 was observed in 85.6% of patients after 3 months, PASI90 in 50%, and PASI100 in 23.3%. Throughout the 3-year analysis, PASI90 was persistent in 91.4% and PASI100 in 51.7%. The majority of patients who reached PASI100 showed a trend to maintain the response in the long-term follow-up. No safety issues were identified. Conclusions: Adalimumab is effective and safe in the long-term treatment of psoriatic patients in daily clinical practice. Once patients achieved PASI100, they tended to remain stable in treatment.http://dx.doi.org/10.1080/09546634.2018.1425358psoriasisadalimumablong-term efficacy |
| spellingShingle | Elizabeth Adenubiova Petr Arenberger Petra Gkalpakioti Monika Arenbergerova Jitka Jircikova Tomas Dolezal Spyridon Gkalpakiotis Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic Journal of Dermatological Treatment psoriasis adalimumab long-term efficacy |
| title | Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic |
| title_full | Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic |
| title_fullStr | Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic |
| title_full_unstemmed | Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic |
| title_short | Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic |
| title_sort | psoriasis treatment with adalimumab in clinical practice long term experience in a center for biological therapy in the czech republic |
| topic | psoriasis adalimumab long-term efficacy |
| url | http://dx.doi.org/10.1080/09546634.2018.1425358 |
| work_keys_str_mv | AT elizabethadenubiova psoriasistreatmentwithadalimumabinclinicalpracticelongtermexperienceinacenterforbiologicaltherapyintheczechrepublic AT petrarenberger psoriasistreatmentwithadalimumabinclinicalpracticelongtermexperienceinacenterforbiologicaltherapyintheczechrepublic AT petragkalpakioti psoriasistreatmentwithadalimumabinclinicalpracticelongtermexperienceinacenterforbiologicaltherapyintheczechrepublic AT monikaarenbergerova psoriasistreatmentwithadalimumabinclinicalpracticelongtermexperienceinacenterforbiologicaltherapyintheczechrepublic AT jitkajircikova psoriasistreatmentwithadalimumabinclinicalpracticelongtermexperienceinacenterforbiologicaltherapyintheczechrepublic AT tomasdolezal psoriasistreatmentwithadalimumabinclinicalpracticelongtermexperienceinacenterforbiologicaltherapyintheczechrepublic AT spyridongkalpakiotis psoriasistreatmentwithadalimumabinclinicalpracticelongtermexperienceinacenterforbiologicaltherapyintheczechrepublic |